Oncology is one of the most valuable subsectors of the healthcare sector, and for good reason. Cancer is a life-threatening condition. Many types of cancer come with little to no treatment options for patients. Many cancers that do offer plenty of treatment options still have high mortality rates.
The good news is that, driven by the high demand for and value of successful cancer treatments, there is plenty of research going on in the field of oncology, and new treatments are being developed all the time.
With that said, here are 5 oncology stocks that investors should be watching closely:
Inovio Pharmaceuticals (INO): Taking A DNA-Based Approach To Cancer Treatment
Inovio Pharmaceuticals is a clinical-stage biotechnology company that is working on treatments to address a wide range of ailments. In fact, the company has become a household name across the United States due to its work to develop a COVID-19 vaccine.
However, DNA-based vaccines aren’t the only thing that INO is working on. In fact, it’s very active in the oncology space.
At the moment, the company has three clinical programs in the field of oncology. These include:
- MEDI-0457 – Currently in the midst of Phase 2 studies, MEDI-0457 is being developed as a potential treatment option for HPV-related cancers. These include head & neck, cervical, anal, penile, and vulvar cancers.
- INO-5401 – INO-5401 is also in the midst of Phase 2 development. This program is assessing a DNA-based option for patients with glioblastoma multiforme.
- INO-5151 – Finally, INO-5151 is also in the midst of Phase 2 studies. The treatment is being developed as a potential option against prostate cancer.
Previous studies on all of these treatments have yielded promising efficacy and safety results, suggesting that Inovio Pharmaceuticals DNA-based approach can be incredibly valuable. This, combined with the company’s work in COVID-19 and other ailments, makes INO stock one that’s worth watching closely.
GT Biopharma (GTBP): TriKE Technology Could Be Incredibly Valuable
GT Biopharma is another clinical-stage biotechnology company that’s focused on the development of treatments for a wide range of ailments. Currently, the company has six candidates, either clinical, or preclinical, under development. Three of these candidates are being developed in the field of oncology, including:
- OXS-1550 – Currently under development as a potential option for acute lymphocytic leukemia non-Hodgkin’s lymphoma.
- OXS-3550 – Currently under development for myeloid malignancies.
- OXS-1615 – Finally, OXS-1615 is being developed as a potential option for the treatment of carcinoma.
The claim to fame at GTBP has to do with the company’s proprietary TriKE technology. The company’s TriKEs are tri-specific NK cell engagers that were designed to overcome limitations seen in CAR-T and other antibody therapies. TriKEs are small, single-chain infusion proteins that bind to the CD16 receptor of NK cells. In preclinical studies, this has shown to produce a more potent and long-lasting response, activating NK, or natural killer cells, and helping to lead to positive outcomes.
Importantly, due to the small size of these TriKEs, it is believed that they are better distributed systemically, which has the potential to lead to strong efficacy. All in all, the company’s TriKE technology has the potential to address a wide range of cancers and other ailments, including COVID-19, making it a technology that comes with serious potential and making GTBP a stock that should not be ignored.
Clovis Oncology (CLVS): Last Year’s Blues Brought Undervaluation
Last year was a rough year for Clovis Oncology. Unfortunately, while the company launched a commercial oncology product, Rubraca, the treatment, originally approved as an option for patients with advanced ovarian cancer, was met with difficulty in commercial performance, upsetting investors. As a result of the poor performance, the company reported a painful loss, leading to serious declines in the value of the stock.
Nonetheless, we’ve seen the beginning of a strong recovery throughout the first several months of this year. Much of the excitement has to do with the fact that the label on Rubraca has been expanded to include, not only advanced ovarian cancer, but advanced prostate cancer.
This is a huge win for Clovis Oncology as the move has the potential to greatly expand sales. In fact, it is estimated that by the year 2025, with this key indication in mind, the company will generate sales of around $740 million annually.
To put this figure into perspective, the company currently trades with a market cap of around $600 million. So, analysts are expecting that by the year 2025, sales of Rubraca will surpass the company’s current market cap by more than $100 million per year.
Aside from Rubraca, CLVS has several other treatment options under development in the field of oncology. Three of these treatments are in late stages and could be the next treatment options to move to commercialization at the company.
All in all, CLVS is a stock that’s hard to ignore.
The bottom line here is simple. Oncology is one of the highest-value subsectors in the biotechnology space. Picking the right stocks in this space has the potential to yield serious returns.
In my opinion, the three stocks mentioned above have incredible long-run potential, making them worth keeping a close eye on.
Get Free Alerts
Join our free mailing list to receive stock alerts!
This website/newsletter is owned, operated and edited by CNA Finance, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” or “CNA Finance” refers to CNA Finance, LLC. This webpage/newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to publish information and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners do not own any shares in stocks mentioned unless stated in page disclosures. If we own any shares we will list the information relevant to the stock and number of shares here. CNA Finance, parent company to Alpha Stock News, receives payment to publish content and promote publicly traded companies. Pursuant to an agreement between CNA Finance and GT Biopharma, CNA Finance has been hired for a period beginning on 3/1/20 and ending on 4/31/20 to conduct digital advertising and marketing and publicly disseminate information about GTBP via Websites and Email. We have an agreement and have been paid fifteen thousand dollars via bank wire transfer to cover the cost of content production. The agreement was extended on May 25 and will run through June 24, 2020. For this extension, GTBP paid CNA Finance an additional fifteen thousand dollars. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated digital outreach efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of digital outreach marketing, which may end as soon as the marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct and GT Biopharma has not approved the content of this site. Furthermore, CNA Finance often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.